NCRI 2016 | Overcoming drug resistance in ovarian cancer
Stan Kaye, BSc, MD, FRCP, FRCR, FRSE, FMedSci of Royal Marsden NHS Foundation Trust, London, UK discusses drug resistance in ovarian cancer. Chemotherapy is limited as many cancers develop resistance to drugs like carboplatin or taxanes. Analysis of samples from patients with relapsed cancer may offer some answers to understand what mechanisms are used by cancer cells to repair DNA damage. Drugs targeting these mechanisms could be then used to inhibit DNA repair and stop cancer proliferation. Recorded at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK.
Get great new content delivered to your inboxSign up